MASLD, previously known as non-alcoholic fatty liver disease, has become the most prevalent chronic liver condition globally, with an estimated worldwide prevalence of approximately 38 percent based on recent systematic reviews. It ranges from simple fat accumulation to inflammation and fibrosis and can progress to cirrhosis and hepatocellular carcinoma. There are few approved pharmacological treatments, and understanding the underlying molecular drivers is a priority for researchers. Mitochondrial dysfunction has long been recognized as a central feature of MASLD. Mitochondria are the energy factories of the hepatocyte, and when they fail, fatty acids accumulate inside the cell and inflammatory damage follows. Mitophagy — the selective autophagic degradation of damaged mitochondria — is the cell’s quality control system for keeping its mitochondrial network healthy. Earlier work from other groups has shown that restoring mitophagy, for instance with quercetin or cyanidin-3-O-glucoside, can improve fatty liver disease in animal models, and that impaired mitophagy is a mechanistic biomarker in patients with the disease. But the regulatory circuits that shut mitophagy down during MASLD development have remained incompletely mapped.

The new study, led by Mei Long of the Department of Rheumatology and Immunology at the First Affiliated Hospital of Hengyang Medical School, University of South China, together with Kewei Tan of the No. 922 Hospital of the People’s Liberation Army Joint Logistics Support Force and Yujie Dong of the Department of Ultrasound Medicine at the same institution, set out to fill that gap. The researchers first profiled ZNF143, a zinc finger transcription factor that binds specific GC-rich DNA motifs and acts both as an activator and repressor of transcription. ZNF143 is best studied in cancer biology, where it promotes glioma growth through KPNA2-mediated Hippo signalling and supports breast cancer cell survival through the NQO1–p53–Beclin1 axis under metabolic stress. Prior work by the same team had already implicated ZNF143 in fatty liver disease, showing that it inhibits hepatocyte mitophagy by upregulating the long non-coding RNA NEAT1 and activating the ROCK2 pathway. The current study extends that work by identifying an entirely separate, protein-level arm of the same transcription factor’s suppressive effect on mitochondrial quality control.

To test their hypothesis, the researchers used two complementary models of MASLD. The first was an in vivo model in which C57BL/6J mice were fed a high-fat diet for 16 weeks to induce hepatic steatosis and metabolic stress. The second was an in vitro model in which Huh-7 human hepatoma cells, a standard hepatic cell line, were exposed to free fatty acids to mimic lipid overload. Histological changes were assessed by hematoxylin and eosin staining, lipid accumulation was quantified by Oil Red O staining, and mitochondrial damage was assessed with JC-1 staining to monitor mitochondrial membrane potential and transmission electron microscopy to visualize mitochondrial ultrastructure. Serum and tissue markers of liver injury, including alanine aminotransferase, aspartate aminotransferase, total cholesterol and triglycerides, were measured to gauge the severity of hepatic dysfunction.

When the team examined the high-fat-diet-fed mice and the free-fatty-acid-treated Huh-7 cells, they found that ZNF143 was significantly upregulated in both settings, consistent with a role for this transcription factor in disease progression rather than simply a bystander effect. When the researchers knocked down ZNF143 using RNA interference, the consequences were striking: lipid accumulation in the liver decreased, mitochondrial damage was reduced, and liver injury markers fell. The mechanism behind this improvement was traced to a restoration of hepatocyte mitophagy, confirming that ZNF143 acts as a brake on mitochondrial quality control during MASLD.

The next step was to identify the transcriptional target through which ZNF143 exerts its effect. Using chromatin immunoprecipitation, the researchers demonstrated that ZNF143 binds directly to the promoter region of SMURF1, a HECT-type E3 ubiquitin ligase known for its role in ubiquitinating and degrading diverse substrate proteins in cancer, vascular remodeling and inflammatory signalling. Dual-luciferase reporter assays confirmed that this binding functionally activates SMURF1 transcription. In other words, ZNF143 does not merely correlate with MASLD; it actively turns up the expression of a ubiquitin ligase that then acts downstream.

SMURF1 has a complicated history in liver biology. Previous studies have shown that deleting Smurf1 attenuates liver steatosis in mice by stabilizing p53, and that Smurf1 aggravates fatty liver disease by stabilizing SREBP-1c, a master regulator of lipid synthesis, in an E3-activity-independent manner. Conversely, another study reported that SMAD-specific E3 ubiquitin protein ligase 1 can be protective in alcoholic steatohepatitis. The current study adds a new substrate to SMURF1’s growing portfolio in hepatic disease and clarifies how this E3 ligase suppresses mitochondrial quality control. Using co-immunoprecipitation, the team showed that SMURF1 physically interacts with TRPV1, the transient receptor potential vanilloid type 1 ion channel, and that SMURF1 ubiquitinates TRPV1, leading to its proteasomal degradation. TRPV1, the receptor activated by capsaicin, the pungent compound in chili peppers, has long been linked to metabolic health. Activation of TRPV1 by dietary capsaicin improves visceral fat remodelling through calcium influx, and TRPV1 activation prevents fatty liver disease in mice through upregulation of the mitochondrial uncoupling protein UCP2. By degrading TRPV1, SMURF1 removes a protective channel that supports mitochondrial and metabolic homeostasis in the hepatocyte.

The researchers then performed epistasis experiments to confirm the hierarchy of the pathway. When they knocked down TRPV1 in free-fatty-acid-treated Huh-7 cells that had already had ZNF143 depleted, the beneficial effect of ZNF143 knockdown on mitophagy was reversed. Similarly, overexpressing SMURF1 in ZNF143-depleted cells abolished the improvement in mitochondrial clearance. These results established that ZNF143 acts upstream of SMURF1 and TRPV1 in the same linear pathway: ZNF143 turns on SMURF1 transcription, SMURF1 ubiquitinates TRPV1 and targets it for degradation, and loss of TRPV1 suppresses mitophagy, leading to mitochondrial dysfunction and fat accumulation.

The significance of the finding is twofold. First, it adds to the emerging view that MASLD is fundamentally a disorder of impaired mitochondrial turnover, not simply one of excessive lipid synthesis. Multiple groups have shown that PINK1/Parkin-mediated mitophagy relieves fatty liver disease and that reversing Parkin-related mitophagy attenuates the condition. The current work identifies ZNF143 as a transcriptional switch that turns this quality control system off, providing a mechanistic explanation for why mitophagy declines during disease progression. Second, the study places TRPV1 — a channel best known from pain biology and dietary capsaicin research — at the centre of hepatic mitochondrial homeostasis. Recent work has implicated TRPV1 in mitophagy regulation in other contexts as well, including a 2025 report showing that TRPV1 inhibits both ferroptosis and mitophagy in heart failure through SFXN2, and a 2020 study showing that blocking TRPV1 promotes terminal mitophagy in multiple myeloma. The context-dependent role of TRPV1 in mitophagy across different tissues remains an open question, but the current study firmly establishes it as a downstream effector of ZNF143 in hepatocytes.

Therapeutically, the pathway offers several potential points of intervention. Small-molecule inhibitors of ZNF143 activity have already been developed for cancer applications, including YPC-21661 and YPC-22026, which were shown to inhibit ZNF143 activity both in vitro and in vivo. Inhibitors of SMURF1 have been designed for pulmonary arterial hypertension, suggesting that pharmacological tools against this E3 ligase could be repurposed for metabolic liver disease. Alternatively, TRPV1 agonists such as capsaicin or its analogues could theoretically compensate for the loss of TRPV1 protein caused by SMURF1-mediated degradation, consistent with epidemiological and experimental data suggesting that capsaicin may promote vascular and metabolic health. The authors note that the study’s findings, generated in mice and in a human hepatoma cell line, will need to be validated in human tissue samples and in additional model systems before any clinical translation.

The research was performed in accordance with guidelines approved by the Medical Ethics Committee of the First Affiliated Hospital of University of South China, and all authors declare no conflict of interest. The datasets generated and analysed during the study are available within the published article. As global rates of MASLD continue to climb in parallel with obesity and type 2 diabetes, identifying transcription factors such as ZNF143 that govern mitochondrial quality control provides a mechanistic framework for understanding disease progression and offers a roadmap for developing targeted therapies that restore the hepatocyte’s ability to clear its damaged mitochondria before steatosis spirals into inflammation, fibrosis and cancer.

Hepatic steatosis, commonly referred to as fatty liver, is a hallmark of metabolic syndrome and often precedes more severe liver conditions such as steatohepatitis, fibrosis, and cirrhosis. The condition is characterized by the abnormal accumulation of triglycerides within hepatocytes, which can trigger local inflammation and cellular stress leading to liver damage. Despite decades of research, the precise molecular communications between adipose tissue and the liver that exacerbate this lipid dysregulation remain underexplored. This new study has focused on extracellular vesicles as vehicles of molecular messages between tissues, deciphering how adipocyte-secreted sEVs influence hepatic lipid homeostasis.

Extracellular vesicles, particularly small exosomes ranging from 30 to 150 nanometers, are released by virtually all cell types and serve as carriers of nucleic acids, proteins, and lipids. These vesicles are now recognized as crucial mediators of intercellular signaling. In adipocytes, sEVs encapsulate a spectrum of miRNAs, which upon delivery to target cells, regulate gene expression programs essential for maintaining metabolic balance. The researchers identified that miR-30a-3p is abundantly packaged into adipocyte-derived sEVs in mice fed a high-fat diet, suggesting diet-induced changes in vesicle cargo.

To unravel the impact of miR-30a-3p on the liver, the team employed sophisticated in vivo tracing techniques, confirming that adipocyte-derived sEVs can cross tissue barriers and are taken up by hepatocytes. Once inside liver cells, miR-30a-3p exerts profound effects by downregulating key metabolic regulators involved in lipid catabolism. Notably, the microRNA targets genes that facilitate fatty acid oxidation and mitochondrial function, thereby promoting lipid accumulation within hepatocytes. These molecular cascades illustrate how a single miRNA species delivered via extracellular vesicles can orchestrate complex metabolic derangements.

High-fat diets are known to alter adipocyte function, including changes in vesicle secretion dynamics and cargo composition. The study demonstrated that diet-induced obesity leads to an upregulation of miR-30a-3p expression in adipose tissue, which translates into higher levels of this microRNA in circulating sEVs. This establishes a direct mechanistic link between nutritional excess and molecular communication pathways that disturb liver metabolism. These findings point toward the systemic nature of metabolic diseases, emphasizing the need to consider inter-organ communication when designing interventions.

Intriguingly, the researchers also employed genetic knockdown approaches to silence miR-30a-3p in adipocytes, which resulted in a marked reduction in hepatic steatosis severity in high-fat diet-fed mice. This highlights the potential of therapeutic strategies that target the biogenesis or loading of sEVs, or specifically inhibit problematic miRNAs, as novel treatments for fatty liver disease. Given the challenge of delivering nucleic acid therapeutics efficiently to specific tissue compartments, extracellular vesicles themselves might be engineered as delivery vehicles, opening cutting-edge pathways in nanomedicine.

The work further explored downstream targets of miR-30a-3p within hepatocytes to decode the transcriptional network affected by this microRNA. The repression of PPARα (peroxisome proliferator-activated receptor alpha), a master regulator of lipid oxidation pathways, was particularly notable. Loss of PPARα activity diminishes the liver’s capacity to break down fats, favoring the accumulation of triglycerides. Additionally, miR-30a-3p influenced mitochondrial biogenesis factors, suggesting a broad impairment of hepatocellular energy metabolism. These data collectively underscore the central role of miR-30a-3p in rewiring hepatic metabolic pathways via post-transcriptional regulation.

Importantly, the study design accounted for sex-specific effects by focusing on male mice, given the known differences in fat distribution and metabolism between sexes. This approach acknowledges the complexity of metabolic disease phenotypes and the necessity to explore how extracellular vesicle-mediated mechanisms may vary by sex. Future research expanding these observations to female models and other metabolic contexts could provide a more comprehensive understanding of miRNA roles under various physiological conditions.

Beyond the molecular insights, the translational implications of this research are significant. Non-alcoholic fatty liver disease (NAFLD) affects millions worldwide and currently lacks targeted pharmacological treatments. Understanding how adipocyte-derived extracellular vesicles contribute to disease progression offers fresh biomarkers for early detection and monitoring of NAFLD. Moreover, circulating miR-30a-3p levels in plasma sEVs could serve as minimally invasive indicators of liver health or metabolic state in patients.

The study’s integrated methodology combined lipidomics, transcriptomics, and functional assays, providing a multifaceted view of the interplay between adipose tissue and the liver. Advanced imaging techniques confirmed vesicle trafficking routes, while RNA sequencing identified gene networks disrupted by miR-30a-3p. This systems biology approach sets a new standard for studying inter-tissue communication in complex metabolic diseases and establishes a framework for investigating other vesicle-associated miRNAs in varied pathologies.

As obesity rates continue to rise globally, unraveling the mechanisms that link disrupted adipocyte function to downstream organ damage is vital. This study redefines the role of adipose tissue beyond fat storage as an active endocrine organ that exploits extracellular vesicles to influence distant tissues negatively. Targeting the molecular conversations mediated by extracellular vesicles represents a paradigm shift in the treatment of metabolic syndrome-associated complications such as hepatic steatosis.

In conclusion, Zhang and colleagues have masterfully demonstrated that small extracellular vesicles secreted by adipocytes are not merely byproducts but active vehicles of pathological signals. The delivery of miR-30a-3p to hepatocytes disrupts critical metabolic pathways, driving the progression of fatty liver disease in high-fat diet contexts. This discovery opens exciting possibilities to modulate extracellular vesicle content and communication patterns as therapies for human metabolic disorders.

As researchers continue to dissect the vesicle-mediated miRNA networks in various tissues, the current findings spotlight the complexity and precision of intercellular signaling in health and disease. The future of metabolic medicine may hinge on decoding and manipulating these nanoscale messages, offering hope for millions suffering from obesity-related liver diseases and beyond.

Subject of Research:
The role of adipocyte-derived small extracellular vesicle microRNA-30a-3p in exacerbating hepatic steatosis in male mice subjected to a high-fat diet.

Article Title:
Adipocyte small extracellular vesicle-derived microRNA-30a-3p exacerbates hepatic steatosis in high fat diet-fed male mice.

Article References:
Zhang, T., Hu, L., Chen, D. et al. Adipocyte small extracellular vesicle-derived microRNA-30a-3p exacerbates hepatic steatosis in high fat diet-fed male mice. Nat Commun (2026). https://doi.org/10.1038/s41467-026-71731-2

Image Credits: AI Generated